347740 — P&K Skin Research Center Co Balance Sheet
0.000.00%
- KR₩79bn
- KR₩45bn
- KR₩18bn
- 81
- 59
- 81
- 89
Annual balance sheet for P&K Skin Research Center Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 49,723 | 42,249 | 57,463 | 44,688 | 40,711 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,191 | 1,467 | 2,584 | 5,908 | 5,414 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 51,252 | 44,018 | 60,359 | 51,079 | 48,164 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,531 | 4,618 | 4,571 | 4,639 | 3,639 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 59,892 | 67,094 | 74,539 | 77,407 | 82,040 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,564 | 3,118 | 3,085 | 2,590 | 4,747 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4,265 | 4,027 | 3,732 | 3,204 | 5,104 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 55,626 | 63,067 | 70,807 | 74,203 | 76,935 |
| Total Liabilities & Shareholders' Equity | 59,892 | 67,094 | 74,539 | 77,407 | 82,040 |
| Total Common Shares Outstanding |